Pharming Group N.V. (PHAR), a global biopharmaceutical company developing and commercializing innovative protein replacement therapies and precision medicines for rare diseases, which showcased strong financial performance in the first quarter, is gearing up for a year of remarkable growth.
The company has two commercialized assets - Ruconest and Joenja. Ruconest, approved for the treatment of acute hereditary angioedema (HAE attacks, is marketed in the U.S., Europe and other countries. Joenja, the first and only approved disease modifying treatment for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), is marketed in the U.S.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com